Reference : Does plasminogen activator inhibitor-1 drive lymphangiogenesis?
Scientific journals : Article
Life sciences : Biochemistry, biophysics & molecular biology
http://hdl.handle.net/2268/29627
Does plasminogen activator inhibitor-1 drive lymphangiogenesis?
English
Bruyere, Francoise [> > > >]
Melen-Lamalle, Laurence [> > > >]
Blacher, Silvia mailto [Université de Liège - ULg > Département des sciences cliniques > Labo de biologie des tumeurs et du développement >]
Detry, Benoît mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme >]
Masset, Anne [> > > >]
Lecomte, Julie mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme >]
Lambert, Vincent mailto [Centre Hospitalier Universitaire de Liège - CHU > > Ophtalmologie >]
Maillard, Catherine [Université de Liège - ULg > Département des sciences cliniques > Labo de biologie des tumeurs et du développement >]
Hoyer-Hansen, Gunilla [> > > >]
Lund, Leif R [> > > >]
Foidart, Jean-Michel mailto [Université de Liège - ULg > Département des sciences cliniques > Gynécologie - Obstétrique - Labo de biologie des tumeurs et du développement >]
Noël, Agnès mailto [Université de Liège - ULg > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme >]
2010
PLoS ONE
Public Library of Science
5
3
e9653
Yes (verified by ORBi)
International
1932-6203
San Franscisco
CA
[en] The purpose of this study is to explore the function of plasminogen activator inhibitor-1 (PAI-1) during pathological lymphangiogenesis. PAI-1, the main physiological inhibitor of plasminogen activators is involved in pathological angiogenesis at least by controlling extracellular proteolysis and by regulating endothelial cell survival and migration. Protease system's role in lymphangiogenesis is unknown yet. Thus, based on its important pro-angiogenic effect, we hypothesized that PAI-1 may regulate lymphangiogenesis associated at least with metastatic dissemination of cancer cells. To address this issue, we studied the impact of PAI-1 deficiency in various murine models of tumoral lymphangiogenesis. Wild-type PAI-1 proficient mice were used as controls. We provide for the first time evidence that PAI-1 is dispensable for tumoral lymphangiogenesis associated with breast cancers either induced by mammary carcinoma cell injection or spontaneously appearing in transgenic mice expressing the polyomavirus middle T antigen (PymT) under the control of a mouse mammary tumor virus long-terminal repeat promoter (MMTV-LTR). We also investigated inflammation-related lymphatic vessel recruitment by using two inflammatory models. PAI-1 deficiency did neither affect the development of lymphangioma nor burn-induced corneal lymphangiogenesis. These novel data suggest that vascular remodelling associated with lymphangiogenesis and angiogenesis involve different molecular determinants. PAI-1 does not appear as a potential therapeutic target to counteract pathological lymphangiogenesis.
http://hdl.handle.net/2268/29627
10.1371/journal.pone.0009653
FP7 ; 201279 - MICROENVIMET - Understanding and fighting metastasis by modulating the tumour microenvironment through interference with the protease network.

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Bruyere F Plos One 2010.pdfPublisher postprint4.44 MBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.